Latest Conference Articles

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

These data support using this combination therapy as a new first-line treatment option in patients with previously untreated metastatic or unresectable BTC.

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

It would also be beneficial to include a patient’s entire healthcare team in this management strategy, said an expert at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2023 in Phoenix, Arizona.

Consistent toxicity management and education reinforcement can improve the patient’s treatment management strategy.

It is a means of supporting the growing provider status movement, which could enable clinical practice growth.

Expert discusses the updated guidelines for treating diabetes at the American Pharmacists Association (APhA) 2023 Meeting & Exposition in Phoenix, Arizona.

Improving the process of safe medication therapy management requires comfort, trust, and fostering a culture for safe communication.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

Factors (comorbidities, social factors) can largely affect the success of therapies in daily practice, despite findings observed in clinical trials.

And whatever specialty the student or resident decides on, it does not have to define the rest of their career.

Creating a safe environment for LGBTQ+ patients through the use of trauma informed care is critical to ensuring they feel comfortable returning to the clinic in the future.

There has been a historical lack of complete or appropriate data on sexual and gender minority groups, leading to difficulties in analyzing health outcomes in LGBTQ+ community.

Despite the potential for clinical benefit, triplet therapies have added complexities, monitoring needs, toxicities, and costs associated with additional pharmacologic therapy.

If patients with G6PD deficiency are exposed to risk factors, such as certain medications, environmental factors, or foods, it can lead to hemolysis.

Pharmacists have an important role in helping patients to identify treatment-related toxicities and manage symptoms to help the transition to the outpatient setting.

Some specialty pharmacy programs are even using electronic medical records to send survey tools to patients.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

The Hematology/Oncology Pharmacy Association (HOPA) created committees, inclusion statements, and diversity, equity, and inclusion (DEI) checkpoints to improve healthcare for underserved or historically less included populations.

Before tapering patients treated for cancer off of opioids, care providers should first establish what the goals of tapering are.

Certain populations have been found to have differing prognoses, such as African American patients, who have an earlier onset of disease with a higher likelihood of an aggressive tumor type and shorter survival.

Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.

Legal expert breaks down the history of power between federal v. state law and why Dobbs v. Jackson has caused such a stir for the pharmaceutical community.

Historically, there are many hard-to-treat mutations of non-small cell lung cancer.